Aspira Womens HealthAWHL +7.07%36 Days Inventory is 27.90 as of Mar. 2026, which is 129% above its 10-year median of 12.20. GuruFocus rates AWHL with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 177 Medical Diagnostics & Research companies, Aspira Womens Health ranks better than 77.97% on this metric.
The historical rank and industry rank for Aspira Womens Health's Days Inventory or its related term are showing as below:
AWHL'
s Days Inventory Range Over the Past 10 Years
Min: 2.94 Med: 12.2 Max: 32.18
Current: 28.61
During the past 13 years, Aspira Womens Health's highest Days Inventory was 32.18. The lowest was 2.94. And the median was 12.20.
AWHL's Days Inventory is ranked better than 77.97% of 177
companies
in the Medical Diagnostics & Research industry
Industry Median: 70.8
vs AWHL: 28.61
Aspira Womens Health's Days Inventory
declined
from Mar. 2025 (37.19) to Mar. 2026 (27.90).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Aspira Womens Health's Inventory Turnover for the
three
months ended in Mar. 2026 was 3.27.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aspira Womens Health's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.14.
Aspira Womens Health (OTCPK:AWHL) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Aspira Womens Health's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aspira Womens Health's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Aspira Womens Health Days Inventory Related Terms
Aspira Womens Health Days Inventory Historical Data
* Premium members only.
The historical data trend for Aspira Womens Health's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AWHL vs MDXH, BIOQ, XWEL: Days Inventory Comparison
For the Diagnostics & Research subindustry, Aspira Womens Health's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Days Inventory distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (AWHL) has a Days Inventory of 27.90 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Aspira Womens Health and its competitors. This is 129% above median its historical median of 12.20. Over the past decade, Aspira Womens Health's Days Inventory has ranged from 2.94 to 32.18. According to the industry distribution chart, Aspira Womens Health ranks #39 out of 177 companies in the Medical Diagnostics & Research industry, placing it in the top 22%.
Is Aspira Womens Health's Days Inventory too high?
Aspira Womens Health's current Days Inventory of 27.90 is 129% above median its 10-year median of 12.20. Over the past 10 years, this metric has ranged from a low of 2.94 to a high of 32.18. The Medical Diagnostics & Research industry median Days Inventory is 70.80. Aspira Womens Health's value of 27.90 is 60.6% below this industry median. Based on the distribution chart, Aspira Womens Health ranks #39 out of 177 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Aspira Womens Health has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's Days Inventory compare to MDXH and BIOQ?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #39 out of 177 companies for Days Inventory. This places Aspira Womens Health in the top 22% of its industry — outperforming the majority of peers. The industry median Days Inventory is 70.80. Aspira Womens Health's value of 27.90 is 60.6% below this benchmark. Historically, Aspira Womens Health's own Days Inventory has ranged from 2.94 to 32.18 over the past decade. While the company's 10-year median is 12.20 vs. the industry median of 70.80, Aspira Womens Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 70.80, based on 177 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspira Womens Health's current Days Inventory of 27.90 is 60.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Aspira Womens Health and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 70.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Womens Health's current Days Inventory is 27.90, which is 129% above median its own 10-year median of 12.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.42 — trading 50% above its estimated fair value. The current Days Inventory is 27.90, which is 129% above median its 10-year median of 12.20 and 60.6% below the Medical Diagnostics & Research industry median of 70.80. Aspira Womens Health's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current Days Inventory is 27.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.42 is trading 50% above its estimated GF Value™ of $0.28.
GuruFocus considers Aspira Womens Health to be Significantly Overvalued.
Key valuation signals for AWHL:
Days Inventory: 27.90 (129% above median its 10-year median of 12.20)
GF Value™: $0.28 vs. price of $0.42 (50% above fair value)
Industry Position: 60.6% below the Medical Diagnostics & Research median (#39 of 177)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
36GF Score
Get the complete analysis for AWHL
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
